$19.11
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. The company is headquartered in Summit, New Jersey and currently employs 21,780 full-time employees. The company went IPO on 2023-05-04. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
Country

US

CEO

Mr. Kirk Perry

IPO date

2023

Employees

21,890

ISIN

US49177J1025

Key stats

Open

$18.92

Volume

17.70M

Market cap

$36.36B

Prev. close

$18.93

Impl / hst vl

-

Open interest

$0.00

$18.87

Day’s Range

$19.16

$16.56

52W Range

$20.13

Valuation

61
Valuation score
Undervalued
P/E
22.24
P/S
2.39
P/B
3.49
Current ratio
1.01
Debt / Equity
0.80
ROE
15.58%
Gross margin
58.58%
Income growth
-3.80%
FCF growth
78.29

Aug

26

Dividends

The last payment date was Aug 26, 2026

Div. per Share

$0.21

Div. Yield

1.11%

Payout Ratio

-

Div. Growth YoY

1.20%

Analysts estimates

Consensus rating
Hold

The average rating from top 14 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$20.41
The top 16 analysts forecasts that 12-month price may increase by 6.80%, with a low of $18.18 and a high of $25.32
$18.18
Low
$20.41
Avg
$25.32
High
Current price

Earnings

Q2 ‘26 revenue
$3.96B
Q2 ‘26 net income
$456.00M
Revenue
Net income
Previous EPS
$0.32
Estimate EPS
$0.33
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply